RxDoctor Payments Data

Christina Saurel, MD

Hematology & Oncology · Gainesville, GANPI 1104025154

Payments from drug & device makers

$10,892in general payments, 2019–2025

Across 456 payments — averaging $23.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bristol Myers Squibb$2K
  • AbbVie$585
  • Seagen Inc.$514
  • E.r. Squibb & Sons, L.L.C.$498
  • Pfizer$466
  • AstraZeneca$445
  • plus $6K from 54 others

What the payments were for

  • Consulting fees$1,66315%
  • Food & beverage$8,93282%
  • Education$2973%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Bristol Myers Squibb34$2,403
AbbVie22$585
Seagen Inc.31$514
E.r. Squibb & Sons, L.L.C.24$498
Pfizer25$466
AstraZeneca(2 entities)22$445
Johnson & Johnson15$415
Merck19$332
GSK15$286
Novartis14$286
Amgen16$272
Exelixis Inc.12$266
Daiichi Sankyo Inc.15$259
Ipsen Biopharmaceuticals, Inc12$251
Incyte Corporation15$250
Gilead(2 entities)14$219
Genentech USA, Inc.9$206
Sanofi11$192
Eisai Inc.9$183
Takeda Pharmaceuticals U.S.A., Inc.7$151
Array Biopharma Inc14$128
Verastem, Inc.1$125
Epizyme, Inc.7$121
ASD Specialty Healthcare, LLC1$114
Regeneron Healthcare Solutions, Inc.5$111
Caris MPI, Inc.2$96
Rigel Pharmaceuticals, Inc.5$92
Tempus AI, Inc3$85
Taiho Oncology, Inc.4$85
Astellas Pharma US Inc3$83
Jazz Pharmaceuticals Inc.4$81
Pharmacyclics LLC, An Abbvie Company4$81
Bayer3$77
Blueprint Medicines Corporation4$77
Agios Pharmaceuticals, Inc.3$61
Beigene USA, Inc.2$60
EMD Serono, Inc.2$58
Stemline Therapeutics Inc.3$57
Coherus Oncology, Inc.3$57
Sobi, Inc2$56
Boston Scientific2$40
Adaptive Biotechnologies Corporation2$40
Deciphera Pharmaceuticals Inc.2$38
Karyopharm Therapeutics Inc.2$37
Acrotech Biopharma Inc.2$36
Morphosys, US Inc.2$36
Novocure Inc.1$33
Puma Biotechnology, Inc.2$31
Pharmaessentia USA Corporation2$31
Genmab U.S., Inc.1$26
Lilly USA, LLC2$26
Sumitomo Pharma America, Inc.1$25
Dova Pharmaceuticals1$22
Legend Biotech USA Inc.1$21
Myriad Genetic Laboratories, Inc.1$20
Heron Therapeutics, Inc.2$20
Tersera Therapeutics LLC1$20
Immunocore Limited1$19
ADC Therapeutics America, Inc.1$18
AVEO Pharmaceuticals, Inc.1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,892 in reported general payments places this provider in the 55th percentile of 370 hematology & oncology providers in Georgia.

See all hematology & oncology providers in Georgia

Medicare billing

Part B allowed, 2024
$202,750
Medicare patients
610
Services billed
7,296

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide89$1,149,219
PomalystPomalidomide30$664,686
IbrancePalbociclib40$612,710
RevlimidLenalidomide14$234,182
ImbruvicaIbrutinib13$207,833
ErleadaApalutamide12$181,804
XtandiEnzalutamide16$170,745
Abiraterone Acetate49$164,634
BrukinsaZanubrutinib21$148,188
VenclextaVenetoclax13$140,823
TasignaNilotinib Hcl13$131,331
EliquisApixaban127$95,814
PegasysPeginterferon Alfa-2a11$43,327
XareltoRivaroxaban39$26,975
Exemestane61$5,180

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Eliquis$466$708,524167 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$498$664,68630 claims
Bristol Myers SquibbRevlimid$2,403$234,18214 claims
Johnson & JohnsonErleada, Xarelto$415$208,77951 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$81$207,83313 claims
Astellas Pharma US IncXtandi$83$170,74516 claims
Beigene USA, Inc.Brukinsa$60$148,18821 claims
AbbVieVenclexta$585$140,82313 claims
NovartisTasigna$286$131,33113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 370 hematology & oncology providers in Georgia.

Other hematology & oncology in Gainesville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →